Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen in adults with HIV infection and chronic hepatitis B on antiretroviral therapy
2023-509588-25-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Jan 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen plus background antiretroviral therapy with Placebo plus background antiretroviral therapy (2 arms). Primary endpoint: Composite virologic and serologic response at 36 weeks after scheduled end of treatment. Planned start Jan 2025; status: authorised.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-509588-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509588-25-00.